Circulating microRNAs in plasma as potential biomarkers for the early detection of prostate cancer

Circulating microRNAs in plasma as potential biomarkers for the early detection of prostate cancer INTRODUCTIONProstate cancer screening is accomplished by digital rectal examination (DRE) and serum prostate‐specific antigen (PSA) testing in at risk populations. Men with an elevated age‐specific serum PSA, serum PSA velocity of >0.35 ng/mL per year, or abnormal DRE are believed to be at risk for harboring occult prostate cancer thereby warranting discussion about the merits of prostate needle biopsy. The serum PSA test, however, has limitations in that non‐malignant conditions such as benign prostatic hyperplasia (BPH) and prostatic inflammation can generate non‐specific PSA elevations. Therefore, a high PSA may theoretically yield unnecessary prostate biopsy with resultant complications including infection, bleedings, urinary retention, and pain. Additional concerns entail the psychological stress about possibly having prostate cancer. Therefore, more specific biomarkers for prostate cancer are needed to make a more accurate recommendation for prostate biopsy.MicroRNAs (miRNAs) are small non‐coding RNAs that have the potential to be biomarkers for prostate cancer. They regulate gene expression, post‐transcriptionally, by targeting messenger RNA (mRNAs) and inhibiting their translation. They have been shown to be either down‐regulated or up‐regulated in cancers as well as involved in cellular processes that influence tumorigenesis such as differentiation, proliferation, and apoptosis, thus suggesting their role in cancers. For prostate cancer, studies http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png The Prostate Wiley

Circulating microRNAs in plasma as potential biomarkers for the early detection of prostate cancer

Loading next page...
 
/lp/wiley/circulating-micrornas-in-plasma-as-potential-biomarkers-for-the-early-f8bzM58ibo
Publisher
Wiley
Copyright
© 2018 Wiley Periodicals, Inc.
ISSN
0270-4137
eISSN
1097-0045
D.O.I.
10.1002/pros.23485
Publisher site
See Article on Publisher Site

Abstract

INTRODUCTIONProstate cancer screening is accomplished by digital rectal examination (DRE) and serum prostate‐specific antigen (PSA) testing in at risk populations. Men with an elevated age‐specific serum PSA, serum PSA velocity of >0.35 ng/mL per year, or abnormal DRE are believed to be at risk for harboring occult prostate cancer thereby warranting discussion about the merits of prostate needle biopsy. The serum PSA test, however, has limitations in that non‐malignant conditions such as benign prostatic hyperplasia (BPH) and prostatic inflammation can generate non‐specific PSA elevations. Therefore, a high PSA may theoretically yield unnecessary prostate biopsy with resultant complications including infection, bleedings, urinary retention, and pain. Additional concerns entail the psychological stress about possibly having prostate cancer. Therefore, more specific biomarkers for prostate cancer are needed to make a more accurate recommendation for prostate biopsy.MicroRNAs (miRNAs) are small non‐coding RNAs that have the potential to be biomarkers for prostate cancer. They regulate gene expression, post‐transcriptionally, by targeting messenger RNA (mRNAs) and inhibiting their translation. They have been shown to be either down‐regulated or up‐regulated in cancers as well as involved in cellular processes that influence tumorigenesis such as differentiation, proliferation, and apoptosis, thus suggesting their role in cancers. For prostate cancer, studies

Journal

The ProstateWiley

Published: Jan 1, 2018

Keywords: ; ; ;

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off